Hyper—CVAD／MA方案治疗28例中国人非霍奇金淋巴瘤的有效性及安全性  

Efficacy and safety evaluation for 28 Chinese non-Hodgkin lymphoma patients treated with Hyper- CVAD/MA regimen

作　　者：滕开原[1] 骆卉妍[1] 邱妙珍[1] 李方华[1] 史艳侠[1] 黄慧强[1] 夏忠军[1] 姜文奇[1] 徐瑞华[1] 

机构地区：[1]中山大学肿瘤防治中心内科,广州510060

出　　处：《肿瘤研究与临床》2009年第10期660-662,665,共4页Cancer Research and Clinic

摘　　要：目的评估Hyper-CVAD／MA强化方案治疗28例中国人T细胞性和侵袭性／高度侵袭性B细胞性非霍奇金淋巴瘤患者的有效性和安全性。方法回顾性分析28例2005年1月至2008年9月用Hyper—CVAD／MA方案治疗的初治或复治的B细胞或T细胞非霍奇金淋巴瘤患者的有效性和安全性。结果在27例可评价疗效的包括T细胞和B细胞淋巴瘤的病例中，有效率是70．4％；在13例可评价疗效的B细胞淋巴瘤中，有效率是84．6％。27例患者均发生Ⅲ度或Ⅳ度的骨髓抑制，有2例治疗相关死亡。结论Hyper—CVAD／MA方案治疗中国人T细胞性和侵袭性／高度侵袭性B细胞性非霍奇金淋巴瘤，有效率高，但毒副作用也显著，剂量需要进一步摸索。Objective To evaluate the efficacy and safety of the hyper-CVAD/MA regimen as an intensified treatment option for 28 T cell and aggressive/highly aggressive B cell NHL in Chinese patients. Methods Clinical data of 28 NHL patients treated with hyper-CVAD/MA regimen from Jan 2005 to Sep 2008 were retrospectively analyzed. Results 27 NHL patients were available for the efficacy analysis, with a response rate of 70.4 %. For the 13 B cell lymphoma cases, the response rate was 84.6 %. The main toxicity was Grade Ⅲ or Grade Ⅳ myelosuppression in all cases and 2 treatment related deaths. Conclusion Hyper- CVAD/MA regimen had a high response rate in T cell and aggressive /highly aggressive B cell NHL lymphoma, eompanied by significant toxicity when treating Chinese patients. Further clinical practices are needed to pick up a suitable dose which can balance efficacy and safety.

关 键 词：淋巴瘤 非霍奇金 抗肿瘤联合化疗方案 可重复性 结果 

分 类 号：R733.1[医药卫生—肿瘤]